Anglo-Swedish pharma major AstraZeneca (LSE: AZN) has welcomed a new treatment guideline which recommends its Brilinta (ticagrelor) over clopidogrel in acute coronary syndrome (ACS).
The guidance comes in the American College of Cardiology (ACC) and American Heart Association (AHA) Focused Update on the Duration of Dual Antiplatelet Therapy.
It relates to those who have received a coronary stent and for non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) patients treated with medical therapy alone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze